Long-Term Improvement in Patients with moderate to severe atopic Dermatitis treated with Tralokinumab: An ECZTEND Interim Analysis

被引：0
|
作者：
Beissert, Stefan [1 ]
Blauvelt, Andrew [2 ]
Lacour, Jean-Philippe [3 ]
Toth, Darryl [4 ]
Laquer, Vivian [5 ]
Herranz, Pedro [6 ]
Pink, Andrew [7 ]
Peris, Ketty [8 ]
Fangel, Stine [9 ]
Saeki, Hidehisa [10 ]
Wollenberg, Andreas [11 ]
机构：
[1] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Dermatol, Dresden, Germany
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Univ Hosp Nice Cote Azur, Dept Dermatol, Nice, France
[4] Prob Med Res, Windsor, ON, Canada
[5] First OC Dermatol, Fountain Valley, CA USA
[6] La Paz Univ Hosp, Madrid, Spain
[7] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England
[8] Univ Cattolica Sacro Cuore, Inst Dermatol, Rom, Italy
[9] LEO Pharma AS, Ballerup, Denmark
[10] Nippon Med Sch, Dept Dermatol, Tokyo, Japan
[11] Ludwig Maximilians Univ Munchen, Klinikum LMU Munchen, Klin & Poliklin Dermatol & Allergol, Munich, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2022年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P049
引用
收藏
页码：29 / 30
页数：2
相关论文
共 50 条
  • [11] Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
    Blauvelt, Andrew
    Hong, H. Chih-ho
    Peris, Ketty
    Katoh, Norito
    Tauber, Marie
    Ameen, Mahreen
    Gooderham, Melinda
    Oland, Christian Bjerregard
    Tindberg, Ann-Marie
    Gjerum, Le
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 30 - 31
  • [12] 2-year maintenance of response with tralokinumab in moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial
    Blauvelt, A.
    Lacour, J. -P.
    Toth, D.
    Langley, R.
    Warren, R.
    Pinto, P. Herranz
    Pink, A.
    Simpson, Eric
    Peris, Ketty
    Wollenberg, Andreas
    Le Gjerum
    Fangel, Stine
    Corriveau, Josh
    Schneider, Shannon
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E143 - E144
  • [13] Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab
    Cioppa, Vittoria
    Lazzeri, Laura
    Carraro, Andrea
    De Piano, Ernesto
    Falcinelli, Francesca
    Galluzzo, Marco
    Pallotta, Sabatino
    De Pita, Ornella
    Russo, Filomena
    DERMATITIS, 2024, 35
  • [14] Long-term follow-up in patients with moderate-to-severe atopic dermatitis treated with dupilumab
    Votto, M.
    Fortina, V.
    De Filippo, M.
    Naso, M.
    Villanova, M.
    Licari, A.
    Marseglia, G. L.
    Brazzelli, V.
    ALLERGY, 2023, 78
  • [15] Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
    Blauvelt, Andrew
    Pink, Andrew
    Worm, Margitta
    Langley, Richard G. B.
    Elewski, Boni E.
    Le Gjerum
    Guttman-Yassky, Emma
    JAMA DERMATOLOGY, 2022, 158 (11) : 1327 - 1330
  • [16] BUDGET IMPACT ANALYSIS OF TRALOKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UK
    Chalmers, K.
    Sawyer, L.
    Sohrt, A.
    Robinson, S.
    Ryttig, L.
    Rinciog, C.
    VALUE IN HEALTH, 2022, 25 (12) : S124 - S124
  • [17] Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis
    Cork, Michael J.
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Praestgaard, Amy
    Zhang, Haixin
    Wang, Zhixiao
    Rossi, Ana B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 79 - 79
  • [18] Abrocitinib Long-Term Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study
    Reich, Kristian
    Silverberg, Jonathan I.
    de Bruin-Weller, Marjolein
    Deleuran, Mette
    Beck, Lisa A.
    Papp, Kim
    Farooqui, Saleem A.
    Zhang, Fan
    Feeney, Claire
    Koppensteiner, Herwig
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB116 - AB116
  • [19] Updates on COVID-19 cases and SARS-CoV-2 vaccinations during tralokinumab treatment in moderate-to-severe atopic dermatitis from ECZTEND long-term extension trial
    Langley, R.
    Pink, A.
    Worm, M.
    Costanzo, A.
    Gjerum, L.
    Jorgensen, E.
    Corriveau, J.
    Schneider, S.
    Guttman-Yassky, E.
    Blauvelt, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E144 - E145
  • [20] Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
    Schloesser, Anne R.
    Shareef, Madena
    Olydam, Jill
    Nijsten, Tamar E. C.
    Hijnen, Dirk Jan
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (05) : 510 - 517
12345